{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:10Z","timestamp":1791897010678,"version":"4.3.4"},"reference-count":31,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["R01EY032517"],"award-info":[{"award-number":["R01EY032517"]}]},{"name":"National Institutes of Health","award":["EY036686"],"award-info":[{"award-number":["EY036686"]}]},{"name":"National Institutes of Health","award":["P30 EY08098"],"award-info":[{"award-number":["P30 EY08098"]}]},{"name":"University of Pittsburgh Department of Ophthalmology","award":["R01EY032517"],"award-info":[{"award-number":["R01EY032517"]}]},{"name":"University of Pittsburgh Department of Ophthalmology","award":["EY036686"],"award-info":[{"award-number":["EY036686"]}]},{"name":"University of Pittsburgh Department of Ophthalmology","award":["P30 EY08098"],"award-info":[{"award-number":["P30 EY08098"]}]},{"name":"Campbell Family Foundation, Eye and Ear Foundation of Pittsburgh","award":["R01EY032517"],"award-info":[{"award-number":["R01EY032517"]}]},{"name":"Campbell Family Foundation, Eye and Ear Foundation of Pittsburgh","award":["EY036686"],"award-info":[{"award-number":["EY036686"]}]},{"name":"Campbell Family Foundation, Eye and Ear Foundation of Pittsburgh","award":["P30 EY08098"],"award-info":[{"award-number":["P30 EY08098"]}]},{"name":"University of Pittsburgh Department of Ophthalmology","award":["R01EY032517"],"award-info":[{"award-number":["R01EY032517"]}]},{"name":"University of Pittsburgh Department of Ophthalmology","award":["EY036686"],"award-info":[{"award-number":["EY036686"]}]},{"name":"University of Pittsburgh Department of Ophthalmology","award":["P30 EY08098"],"award-info":[{"award-number":["P30 EY08098"]}]},{"name":"Francis A. L\u2019Esperance, Jr., MD, Visual Sciences Scholar Fund","award":["R01EY032517"],"award-info":[{"award-number":["R01EY032517"]}]},{"name":"Francis A. L\u2019Esperance, Jr., MD, Visual Sciences Scholar Fund","award":["EY036686"],"award-info":[{"award-number":["EY036686"]}]},{"name":"Francis A. L\u2019Esperance, Jr., MD, Visual Sciences Scholar Fund","award":["P30 EY08098"],"award-info":[{"award-number":["P30 EY08098"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Endophthalmitis is an intraocular microbial infection that can lead to permanent blindness, even with prompt anti-microbial therapy. Multi-drug-resistant organisms are on the rise, potentially limiting the efficacy of current empiric antibiotic therapies of intravitreal ceftazidime and vancomycin. Cefiderocol is a recent FDA- and EMA-approved antibiotic for multi-drug-resistant Gram-negative bacteria. Methods: To better understand its potential utility in the treatment of ocular infections, the MIC of cefiderocol was compared to ceftazidime and amikacin in endophthalmitis bacterial isolates using Epsilometer testing. Because vancomycin is commonly given concomitantly as part of empiric endophthalmitis treatment, possible synergistic and antagonistic effects of concomitant vancomycin and cefiderocol were also evaluated. Results: Cefiderocol was found to have lower MIC values compared to ceftazidime for Pseudomonadales or Enterobacterales species. When comparing the MICs of cefiderocol and vancomycin, there appeared to be no antagonism between the two antibiotics. Conclusions: This is the first report exploring the use of cefiderocol in endophthalmitis strains. The results of this study show this is a promising antibiotic for multi-drug-resistant Gram-negative organisms but further research is needed to investigate its intraocular safety profile.<\/jats:p>","DOI":"10.3390\/antibiotics13121236","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:33:29Z","timestamp":1734928409000},"page":"1236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Cefiderocol Against Endophthalmitis Isolates"],"prefix":"10.3390","volume":"13","author":[{"given":"Brennan","family":"Schilling","sequence":"first","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hii","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel Q.","family":"Shanks","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, 1622 Locust St., Pittsburgh, PA 15219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-3276","authenticated-orcid":false,"given":"Eric G.","family":"Romanowski","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, 1622 Locust St., Pittsburgh, PA 15219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Mandell","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, 1622 Locust St., Pittsburgh, PA 15219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M. Q.","family":"Shanks","sequence":"additional","affiliation":[{"name":"The Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, 1622 Locust St., Pittsburgh, PA 15219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zegans","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/bjo-2023-323865","article-title":"Endophthalmitis rates and risk factors following intraocular surgeries in the medicare population from 2016 to 2019","volume":"108","author":"Chen","year":"2024","journal-title":"Br. J. Ophthalmol."},{"key":"ref_2","unstructured":"Gurnani, B., and Kaur, K. (2023). Endogenous Endophthalmitis. StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004397-199603630-00014","article-title":"Endogenous fungal endophthalmitis","volume":"36","author":"Samiy","year":"1996","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0161-6420(00)00079-8","article-title":"Prognostic factors in ocular injuries caused by intraocular or retrobulbar foreign bodies","volume":"107","author":"Jonas","year":"2000","journal-title":"Ophthalmology"},{"key":"ref_5","unstructured":"Simakurthy, S., and Tripathy, K. (2023). Endophthalmitis. StatPearls, StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2147\/OPTH.S17975","article-title":"Delayed-onset bleb-associated endophthalmitis: Presentation and outcome by culture result","volume":"5","author":"Jacobs","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ajem.2023.06.029","article-title":"High risk and low prevalence diseases: Endophthalmitis","volume":"71","author":"Gunalda","year":"2023","journal-title":"Am. J. Emerg. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajo.2013.01.027","article-title":"Endophthalmitis isolates and antibiotic susceptibilities: A 10-year review of culture-proven cases","volume":"156","author":"Schimel","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archopht.1994.01090130055016","article-title":"Empiric treatment of endophthalmitis. Are aminoglycosides necessary?","volume":"112","author":"Donahue","year":"1994","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ophtha.2014.02.001","article-title":"Microbiological spectrum and antibiotic sensitivity in endophthalmitis: A 25-year review","volume":"121","author":"Gentile","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/ceo.13768","article-title":"Gram-negative endophthalmitis: A prospective study examining the microbiology, clinical associations and visual outcomes following infection","volume":"48","author":"Stevenson","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1508","DOI":"10.1002\/hsr2.1508","article-title":"Artificial tears: Promising treatment or silent threat to public health?","volume":"6","author":"Mughal","year":"2023","journal-title":"Health Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100452","DOI":"10.1016\/j.xops.2023.100452","article-title":"Cefiderocol is an effective topical monotherapy for experimental extensively drug-resistant Pseudomonas aeruginosa keratitis","volume":"4","author":"Romanowski","year":"2024","journal-title":"Ophthalmol. Sci."},{"key":"ref_14","unstructured":"Centers for Disease Control and Prevention (2024, December 09). Available online: https:\/\/wwwn.cdc.gov\/ARIsolateBank\/Panel\/IsolateDetail?IsolateID=10561&PanelID=10."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, C., Yang, D., Wang, Y., and Wentao, N. (2022). Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: A systematic review of currently available evidence. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.896971"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New Perspectives on Antimicrobial Agents: Cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","first-page":"45","article-title":"Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance?","volume":"9","author":"Tillotson","year":"2016","journal-title":"Infect. Dis. (Auckl.)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e01009-23","DOI":"10.1128\/aac.01009-23","article-title":"The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy","volume":"68","author":"Teran","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chom.2013.04.010","article-title":"Iron in infection and immunity","volume":"13","author":"Cassat","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/ICL.0000000000000642","article-title":"The prevalence of bacteria, fungi, viruses, and Acanthamoeba from 3,004 cases of keratitis, endophthalmitis, and conjunctivitis","volume":"46","author":"Kowalski","year":"2020","journal-title":"Eye Contact Lens"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: Review of the evidence","volume":"13","author":"Viale","year":"2023","journal-title":"Ann. Intensive Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/archopht.1991.01080070058035","article-title":"Aminoglycoside toxicity\u2014A survey of retinal specialists. Implications for ocular use","volume":"109","author":"Campochiaro","year":"1991","journal-title":"Arch. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.sjopt.2018.09.004","article-title":"Hemorrhagic occlusive retinal vasculitis leading to the diagnosis of ciliary body melanoma","volume":"33","author":"Williams","year":"2019","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee","volume":"8","author":"Witkin","year":"2023","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/mdr.2021.0095","article-title":"Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales","volume":"28","author":"Simner","year":"2022","journal-title":"Microb. Drug Resist."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00198-20","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacaem due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Romanowski, J.E., Nayyar, S.V., Romanowski, E.G., Jhanji, V., Shanks, R.M.Q., and Kowalski, R.P. (2021). Speciation and antibiotic susceptibilities of coagulase negative Staphylococci isolated from ocular infections. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060721"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Harshaw, N.S., Stella, N.A., Lehner, K.M., Romanowski, E.G., Kowalski, R.P., and Shanks, R.M.Q. (2021). Antibiotics used in empiric treatment of ocular infections trigger the bacterial Rcs stress response system independent of antibiotic susceptibility. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091033"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","article-title":"Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test","volume":"40","author":"White","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.prrv.2007.04.006","article-title":"Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: \u2018The motion for\u2019","volume":"8","author":"Saiman","year":"2007","journal-title":"Paediatr. Respir. Rev."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:58:15Z","timestamp":1760115495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/12\/1236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["antibiotics13121236"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13121236","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}